MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Arcutis Biotherapeutics Inc

Cerrado

SectorSalud

13.81 0.15

Resumen

Variación precio

24h

Actual

Mínimo

13.74

Máximo

13.86

Métricas clave

By Trading Economics

Ingresos

-14M

-25M

Ventas

-5.5M

66M

BPA

-0.2

Margen de beneficio

-38.059

Empleados

342

EBITDA

-14M

-19M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+54.05% upside

Dividendos

By Dow Jones

Próximas Ganancias

13 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-145M

1.7B

Apertura anterior

13.66

Cierre anterior

13.81

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

62 / 375 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jul 2025, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

4 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 15:57 UTC

Charlas de Mercado

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 jul 2025, 15:49 UTC

Charlas de Mercado

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Received All Required Authorizations

4 jul 2025, 15:48 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 jul 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Agreement Was Announced on Dec. 19

4 jul 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 jul 2025, 15:46 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 jul 2025, 14:30 UTC

Adquisiciones, fusiones, absorciones

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 jul 2025, 13:53 UTC

Charlas de Mercado

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 jul 2025, 13:41 UTC

Charlas de Mercado

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 jul 2025, 13:41 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 jul 2025, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 12:37 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 jul 2025, 12:37 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 jul 2025, 12:30 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 jul 2025, 12:15 UTC

Charlas de Mercado

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 jul 2025, 12:13 UTC

Charlas de Mercado

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 jul 2025, 12:02 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Arcutis Biotherapeutics Inc Esperado

Precio Objetivo

By TipRanks

54.05% repunte

Estimación a 12 meses

Media 21.29 USD  54.05%

Máximo 29 USD

Mínimo 19 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcutis Biotherapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

12.42 / 14.93Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

62 / 375 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.